Federal Government Urges Lowering Federal Cannabis Restrictions as Rescheduling Hearing Concludes

2026-08-21 politics

Washington, Thursday, 20 August 2026.
The Drug Enforcement Administration filed its final brief advocating to move cannabis to Schedule III, directly challenging opposing experts while internal government testimony reveals stark contradictions on medical safety.

Final Briefs Filed Amidst Policy Contradictions

On August 17, 2026, the Drug Enforcement Administration and opposing parties filed their final post-hearing briefs with Chief Administrative Law Judge Derek Julius, marking a critical juncture in the federal marijuana rescheduling proceeding [1][2]. The DEA’s brief argues that cannabis can no longer remain in Schedule I, relying on a 2023 Department of Health and Human Services recommendation that identified accepted medical uses for treating anorexia, nausea, and pain [2]. However, this federal movement toward Schedule III classification has sparked intense debate, particularly regarding the distinction between medical and adult-use marijuana under the current Trump Administration [4]. While advocates celebrate the potential regulatory shift, the legal record reveals significant friction between federal policy, scientific consensus, and enforcement realities [1]. The filing deadline for these final briefs was confirmed as August 17, 2026, concluding the evidentiary hearing phase that took place from June 29 to July 15, 2026 [2][7].

Scientific Testimony Versus Regulatory Position

A central conflict has emerged within the evidentiary record, where internal government testimony appears to contradict the agency’s current legal position [6]. During the hearings, DEA pharmacologist Dr. Luli Akinfiresoye and FDA official Dr. Dominic Chiapperino testified that marijuana failed the agency’s traditional five-part test for medical use, citing issues with reproducible chemistry and safety evidence [1][6]. Conversely, the government’s brief relies on a 2024 Justice Department Office of Legal Counsel opinion that rejected the traditional five-part test in favor of a two-part HHS inquiry [1]. Duane Boise, CEO of MMJ International Holdings, noted that while advocates may view the brief as a victory, the government cannot erase the sworn record created by its own witnesses [6]. This discrepancy leaves Judge Julius to examine testimonial gaps and statutory requirements before issuing an advisory recommendation to DEA Administrator Terrance Cole [1][6].

Law Enforcement Concerns and Street Reality

While regulatory debates continue in Washington, law enforcement groups highlight ongoing risks associated with the cannabis trade. On August 17, 2026, the Clarksville Police Department defended the seizure of approximately 19.96 kg of marijuana, citing concerns over violence associated with trafficking [1]. This stance is supported by the DEA’s 2025 National Drug Threat Assessment, which highlights that transnational criminal organizations continue to dominate domestic cultivation [1]. The tension is further complicated by the April 2026 order from Acting Attorney General Todd Blanche, which moved state-licensed medical marijuana to Schedule III while leaving adult-use marijuana on Schedule I [4][8]. This split scheduling creates a scenario where the same plant is treated differently under federal law based solely on licensing, a distinction that law enforcement must navigate in the field [5].

Economic Implications and Political Outlook

The economic ramifications of the scheduling distinction extend beyond drug policy into taxation and corporate valuation, specifically regarding Internal Revenue Code Section 280E [5]. In states like Colorado, adult-use marijuana comprised nearly 90 percent of the state’s $1.3 billion marijuana market in 2025, an increase from 66 percent in 2015 [4]. The growth in adult-use market share represents a 36.364 percent increase in market dominance over the decade, underscoring the economic weight of the adult-use sector [4]. Despite the DEA’s current brief, senior Republican leaders and President Trump have not directed the rescheduling of adult-use marijuana, suggesting the broader proposal may face significant political hurdles [4]. As the administrative record moves to DEA Administrator Terrance Cole for final determination, the likelihood of judicial review remains high regardless of the outcome [6].

Sources

Marijuana Policy DEA Reclassification